Arcturus Therapeutics Holdings Inc. (ARCT)
- Previous Close
26.52 - Open
27.64 - Bid 27.09 x 100
- Ask 27.25 x 100
- Day's Range
26.76 - 28.31 - 52 Week Range
17.52 - 43.81 - Volume
196,369 - Avg. Volume
504,979 - Market Cap (intraday)
732.576M - Beta (5Y Monthly) 2.60
- PE Ratio (TTM)
-- - EPS (TTM)
-1.12 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
67.63
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
arcturusrx.comRecent News: ARCT
Performance Overview: ARCT
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARCT
Valuation Measures
Market Cap
714.67M
Enterprise Value
452.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.48
Price/Book (mrq)
2.57
Enterprise Value/Revenue
2.87
Enterprise Value/EBITDA
-18.74
Financial Highlights
Profitability and Income Statement
Profit Margin
-17.82%
Return on Assets (ttm)
-11.11%
Return on Equity (ttm)
-10.83%
Revenue (ttm)
166.8M
Net Income Avi to Common (ttm)
-29.73M
Diluted EPS (ttm)
-1.12
Balance Sheet and Cash Flow
Total Cash (mrq)
292M
Total Debt/Equity (mrq)
10.85%
Levered Free Cash Flow (ttm)
-82.55M